anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides for a human cell atlas of the colon from healthy and diseased subjects. The atlas was obtained by single sequencing of about 117,000 cells. The present invention discloses novel markers for cell types. Moreover, genes associated with disease are identified in the colon and colon specific cell types. The invention provides for diagnostic assays based on gene markers and cell composition, as well as target cell types that express genes associated with disease. Finally, disclosed are novel cell types and methods of quantitating, detecting and isolating the cell types.
OBJECTIVE: Iodine fortification (IF) induces an initial increase followed by a decrease in the incidence of hyperthyroidism in the general population. Within the population of hyperthyroid patients, the sex-, age- and subtype distribution changes after IF. The risk of atrial fibrillation (AF) in hyperthyroid patients may be influenced by these factors. Therefore, we aimed to examine how the association between incident hyperthyroidism and AF was affected by IF increasing the population iodine intake from moderate-mild iodine deficiency to low adequacy. DESIGN, PATIENTS AND MEASUREMENTS: Incident hyperthyroid patients were included at the date of first inpatient or outpatient diagnosis, and AF diagnoses within 3 months before to 6 months after the index date were identified in Danish nationwide registers, 1997-2018. The relative risk (RR) of AF each calendar year (reference: 1997; IF introduced: 2000) was analyzed in Poisson regression models adjusted for age, sex, educational level, geographic region, and comorbidities.
RESULTS: Overall, in 62,201 patients with incident hyperthyroidism 7.9% were diagnosed with AF. There was a minor nonsignificantly increased risk of AF during the first years after IF followed by a gradual decrease to RR 0.76 (0.62-0.94) in 2017. There were no statistically significant differences in the development in the risk of AF by sex, age group, or geographic region.
CONCLUSIONS: Results indicate that IF may reduce the risk of concomitant AF in hyperthyroid patients. If these results are confirmed, IF may not only reduce the population incidence of hyperthyroidism but also reduce the burden of morbidity in the remaining hyperthyroid patients.
Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
INTRODUCTION: This study investigated the effects of falls on self-rated health and anxiety symptoms and the moderating role of psychological resilience in Chinese older persons with chronic multimorbidity.
METHODS: Data were taken from the 2018 Chinese Longitudinal Healthy Longevity Survey (CLHLS). We used a linear regression model to evaluate the associations among falls and self-rated health and anxiety symptoms, the moderating role of psychological resilience was verified by moderation analysis, and we also used a replacement model to test robustness. Finally, the results of the study were further verified via heterogeneity analysis through subgroup regression.
RESULTS: A total of 2933 people aged 60 years or older with chronic multimorbidity were included in our study. The linear regression results revealed that falls were significantly negatively correlated with the self-rated health symptoms of older Chinese people with chronic multimorbidity (β = -0.1703, p < 0.01) and significantly positively correlated with anxiety symptoms (β = 0.5590, p < 0.01). Among the moderating effects, we found that psychological resilience played a moderating role between falls and anxiety symptoms (β = - 0.151 [-0.217, -0.084], p < 0.01). Finally, we found heterogeneity in the study results by sex, residence and number of chronic diseases.
CONCLUSION: Falls are associated with poorer self-rated health and higher anxiety levels among older persons with chronic multimorbidity in China. High levels of psychological resilience have a moderating effect on the development of anxiety symptoms.
1460053 6,7-Benzomorphans SUMITOMO CHEMICAL CO Ltd 1 April 1974 [31 March 1973] 14320/74 Heading C2C Novel compounds of Formula I wherein R 1  is H, C 1-5  alkyl or acyl, R 2  and R 3  are each C 1-5  alkyl and A is C 1-5  alkyl, cyano(C 1-5 )- alkyl, benzoyl(C 1-5 )alkyl where benzoyl is optionally substituted, e.g. by C 1-5  alkyl, C 1-3  alkoxy or halogen, ar(C 1-5 )alkyl where the aryl group may optionally be substituted, e.g. by C 1-3  alkyl or NO 2 , C 2-5  alkenyl or cyclo C 3-5  alkyl C 1-5  alkyl where the cycloalkyl rings may optionally be substituted, e.g. by C 1-3  alkyl are prepared by one of the following methods (a) a compound of Formula V is reacted with a reactive derivative of A<SP>1</SP>OH where A<SP>1</SP> is A or a benzoyl C 1-5  alkyl group the keto group of which is protected, (b) cyclization of a compound of Formula VIII (c) a compound of Formula V above with CH 2  = CHM where M is cyano or benzoyl; Hofmann degradation of a compound of Formula XI where E is aryl cyano nitro or acyl carboxyl or carbalkoxy and X is halogen and Ar is phenyl, halophenyl or C 1-5  alkoxyphenyl; (d) reductively eliminating the arylmethyl group Ar<SP>1</SP>CH 2  from a compound of formula or by oxidation of a compound of Formula XV wherein n is 1 or 2. Intermediates of Formula XV above are prepared by reduction of a compound of Formula XIV obtained by reaction of ArCO(C n H 2n )COhalogen with a 2 - unsubstituted - 6,7 - benzomorphan derivative of Formula V above. Intermediates of Formula XVII are prepared by reaction of R 1 OPbCH 2 M 3 X with a compound of Formula XVI Pharmaceutical compositions in conventional forms for oral or parenteral administration and having analgesic and antitussive activity comprise an above novel compound and a carrier or diluent.
Anti-haemophilic globulin (Factor VIII) is stabilised in aqueous solution by the addition thereto of one or more clinically acceptable, nonreactive, natural or synthetic water soluble polymeric substances.  Specified are soluble proteins such as non antigenic gelatin, human serum proteins e.g. serum albumin, serum gamma globulin, synthetic nitrogenous polymers such as polyvinylpyrrolidone, nitrogenfree synthetic hydrophilic polymers such as polyethylene glycol or polyvinyl alcohol, natural and synthetic polysaccharides e.g. dextran.  The stabilized solution may be dialysed, subjected to sterile filtration and freeze dried.  The protective agent may be added to the eluting solution or to the eluate obtained in the process described in Specification 883,549 wherein a purified A.H.G. solution is obtained by treating crude A.H.G. solution with an ion exchanger at a pH of 6 to 8.
There is disclosed a method of treating an individual infected with a macrophage pathogen comprising administering an effective amount of a TGF-.beta. antagonist, Macrophage pathogens include any pathogenic microorganism that replicates within macrophage cell hosts as their exclusive or primary host cells. TGF-.beta. antagonists include blocking antibodies specific for a human TGF-.beta., soluble TGF-.beta. receptors, protease inhibitors that inactivate a protease responsible for activating a precursor TGF-.beta. into an active, mature TGF-.beta., and combinations thereof.
Current chemotherapies used to treat ovarian cancer participants include doxorubicin, topotecan, and paclitaxel, to mention a few. Doxorubicin was studied in ovarian cancer participants that were refractory to paclitaxel and platinum-based chemotherapy agents. Inhibition of angiogenesis is considered a promising approach to the treatment of cancer. Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and is likely an important therapeutic target in persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. VEGF is overexpressed in ovarian tissue and may be the most important single tumor angiogenic factor. Phase 1 studies currently nearing completion with ramucirumab have demonstrated safety and tolerability at clinically relevant doses, with preliminary evidence of clinical efficacy in ovarian cancer participants. Therefore, ImClone Systems plans to conduct a Phase 2 trial to assess the safety and efficacy of ramucirumab in participants with platinum-refractory persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
DLBCL mostly occurs in the elderly, with a median age at diagnosis of 66 years. Age over 60 years is a poor prognostic factor for DLBCL and is included in the International Prognostic Index (IPI) to stratify patients for prognosis. So there is an unmet need for treatment in this population. Both lenalidomide and BTK inhibitor single drugs have shown certain efficacy in DLBCL patients, and many studies have also explored the effectiveness of rituximab, lenalidomide and BTK inhibitor combination regimen in the treatment of DLBCL. Therefore, the investigators plan to use ZR2 regimen(rituximab, lenalidomide and zanubrutinib) for 2 cycles to reduce tumor burden, improve the patient's physical condition, and improve the tolerance to immunochemotherapy in elderly newly diagnosed DLBCL patients. Up to 4 cycles of immunochemotherapy were then administered sequentially in order to reduce the overall chemotherapy intensity of the patients and improve the long-term quality of life of the patients.
The present invention relates to a Japanese buttercup herb injection and a series of preparations thereof, which belongs to herbal preparations for medical application. The series of preparations can be various preparations prepared by processing the whole Japanese buttercup herb belonging to a ranunculus in buttercup. The Japanese buttercup herb injection is a clear transparent liquid with yellow brown, and each milliliter of injection is equivalent to 1 gram of dry Japanese buttercup herb. Through animal toxicity tests, the Japanese buttercup herb injection does not have toxicity. 1058 cases of clinical therapeutic results indicate that the cure rate of the Japanese buttercup herb injection for treating hyperosteogeny in an injection mode at a pain point is over 85%, and the total effective rate is over 98%. Simultaneously, the Japanese buttercup herb injection also has an obvious effect on improving microcirculation, and does not have harmful effects on other physiological functions. Thus, the Japanese buttercup herb injection is an ideal preparation for alleviating pain and resisting inflammation.
Hypersensitivity Reactions

Sulfite-Related Reactions

Mesalamine rectal suspension enema contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low. Sulfite sensitivity is seen more frequently in asthmatic or in atopic nonasthmatic persons. 

Epinephrine is the preferred treatment for serious allergic or emergency situations even though epinephrine injection contains sodium or potassium metabisulfite with the above-mentioned potential liabilities. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite(s) in epinephrine injection should not deter the administration of the drug for treatment of serious allergic or other emergency situations.

Sulfasalazine-Associated Reactions

Hypersensitivity reactions have been reported in patients taking sulfasalazine. Some patients may have a similar reaction to mesalamine rectal suspension enema or to other compounds that contain or are converted to mesalamine.

As with sulfasalazine, mesalamine-induced hypersensitivity reactions may present as internal organ involvement, including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis and hematologic abnormalities. Evaluate patients immediately if signs or symptoms of a hypersensitivity reaction are present. Discontinue mesalamine rectal suspension enema if an alternative etiology for the signs and symptoms cannot be established.

Renal Impairment

Renal impairment, including minimal change disease, acute and chronic interstitial nephritis, and renal failure have been reported in patients given products that contain mesalamine or are converted to mesalamine. In animal studies, the kidney was the principal organ of mesalamine toxicity.

Evaluate the risks and benefits of using mesalamine rectal suspension enema in patients with known renal impairment or a history of renal disease or taking concomitant nephrotoxic drugs. Mesalamine is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Evaluate renal function in all patients prior to initiation and periodically while on mesalamine rectal suspension enema therapy. Discontinue mesalamine rectal suspension enema if renal function deteriorates while on therapy.

Mesalamine-Induced Acute Intolerance Syndrome

Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Although the exact frequency of occurrence cannot be ascertained, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache, and rash. Monitor patients for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with mesalamine rectal suspension enema.
PURPOSE: This study was designed to explore the effects of interleukin 33 (IL-33) on the progression of atherosclerosis and the possible mechanism.
METHODS: The adhesion assay was performed on isolated peripheral blood mononuclear cells (PBMCs) and human umbilical vein endothelial cells (HUVEC). The expression of proteins and messenger RNA (mRNA) were detected by western blot and quantitative real-time polymerase chain reaction (PCR), including intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and P-selectin. The effect of IL-33 on the interaction of growth stimulation expressed gene 2 (ST2) with myeloid differentiation factor 88 (MyD88) and interleukin-1 receptor-associated kinase (IRAK) 1/4 were investigated using co-immunoprecipitation assay. An apolipoprotein (Apo) E-/- mice model was used to confirm the effect of IL-33 on atherosclerosis progression. Area of plaques was recorded by hematoxylin-eosin (H&E) staining. The severity of atherosclerosis plaque was evaluated using immunohistochemistry assay, and lipid accumulation was measured by an oil red O staining. In contrast, western blot was performed to detect the expression levels of VCAM-1, extracellular signal-regulated kinase (ERK) 1/2, and interferon regulatory factor 1 (IRF1).
RESULTS: Our study observed that IL-33 suppressed cell adhesion and the expression of VCAM-1 in tumor necrosis factor-α (TNF-α) exposed HUVEC. Moreover, the addition of IL-33 significantly inhibited the expression of IRF1 and the binding level of IRF1 to VCAM-1 and also promoted the phosphorylation level of IRAK1/4 and ERK1/2 compared to TNF-α-stimulated HUVEC. The ST2 neutralizing antibody or ERK pathway inhibitor SCH772984 reversed the regulatory effects of IL-33 on HUVEC, suggesting that IL-33 suppressed IRF1 and VCAM-1 dependent on binding to ST2 and activating the ERK1/2 signaling pathway. Further investigation in vivo confirmed that IL-33 decreased the expressions of IRF1 and VCAM-1 by activating the phosphorylation of ERK1/2 in the thoracic aorta of Apo E-/- mice.
CONCLUSION: In conclusion, our results demonstrated that IL-33 plays a protective role in the progression of atherosclerosis by inhibiting cell adhesion via the ERK1/2-IRF1-VCAM-1 pathway. This study may provide a potential therapeutic way to prevent the development of atherosclerosis.
Rationale: Sepsis care delivery-including the initiation of prompt, appropriate antimicrobials-remains suboptimal. Objectives: This study was conducted to determine direct and off-target effects of emergency department (ED) sepsis care reorganization. Methods: This pragmatic pilot trial enrolled adult patients who presented from November 2019 to February 2021 to an ED in Utah before and after implementation of a multimodal, team-based "Code Sepsis" protocol. Patients who presented to two other EDs where usual care was continued served as contemporaneous control subjects. The primary outcome was door-to-antimicrobial time among patients meeting Sepsis-3 criteria before ED departure. Secondary and safety outcomes included all-cause 30-day mortality, antimicrobial utilization and overtreatment, and antimicrobial-associated adverse events. Multivariable regression analyses used difference-in-differences methods to account for trends in outcomes unrelated to the studied intervention. Results: Code Sepsis protocol activation (N = 307) exhibited 8.5% sensitivity and 66% positive predictive value for patients meeting sepsis criteria before ED departure. Among 10,151 patients who met sepsis criteria during the study, adjusted difference-in-differences analysis demonstrated a 13-minute (95% confidence interval = 7-19) decrease in door-to-antimicrobial time associated with Code Sepsis implementation (P < 0.001). Mortality and clinical safety outcomes were unchanged, but Code Sepsis implementation was associated with increased false-positive presumptive infection diagnoses among patients who met sepsis criteria in the ED and increased antimicrobial utilization. Conclusions: Implementation of a team-based protocol for rapid sepsis evaluation and treatment during the coronavirus disease (COVID-19) pandemic's first year was associated with decreased ED door-to-antimicrobial time but also increased antimicrobial utilization. Measurement of both patient-centered and off-target effects of sepsis care improvement interventions is essential to comprehensive assessment of their value. Clinical trial registered with www.clinicaltrials.gov (NCT04148989).
Applicant discloses methods for treating a glucocorticoid receptor positive (GR + ) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in subject. The GR +  neuroepithelial tumor may be a neurofibromatosis type 2 (NF 2) tumor; the GR +  neuroepithelial tumor may be a schwannoma, meningioma, or ependymoma. In embodiments, the GR +  neuroepithelial tumor is not an adrenocorticotropic hormone (ACTH)-secreting tumor. In embodiments, the SGRM comprises a steroidal backbone. In embodiments, the SGRM is mifepristone. In embodiments, the SGRM comprises a non-steroidal backbone, such as, e.g., a cyclohexyl pyrimidine, a fused azadecalin, a heteroaryl ketone fused azadecalin, or an octahydro fused azadecalin backbone. The SGRM may be administered orally. The SGRM may be administered alone. In embodiments, the SGRM is administered with at least one non-SGRM therapy, e.g., a chemotherapy, a radiation therapy, or other therapeutic agents.
The invention relates to medicine for treating uterine fibroids, in particular to a traditional Chinese medicine oral decoction for treating uterine fibroids. The traditional Chinese medicine oral decoction is prepared from Chinese herbal medicines. According to the technical scheme, the traditional Chinese medicine oral decoction comprises, by weight, 5-8 parts of rhizoma sparganii, 15-20 parts of cortex moutan, 5-8 parts of rhizoma curcumae, 1-3 parts of woodlouse, 1-3 parts of ramulus cinnamomi, 10-13 parts of semen persicae, 15-20 parts of radix angelicae sinensis, 10-13 parts of carapax trionycis, 2-4 parts of hirudo, 10-13 parts of radix paeoniae rubra, 1-3 parts of rhizoma bolbostemmae, 1-3 parts of squama manitis, 1-2 parts of radix bupleuri and 4-12 parts of radix astragali. According to present invention, the components of the traditional Chinese medicine oral decoction are combined to complement each other, and the traditional Chinese medicine oral decoction has the effects of tonifying and activating the blood, freeing the collateral vessels to dissipate stasis, regulating menstruation to stop pains, strengthening the spleen and stomach, calming the heart for tranquillizing, clearing heat to cool the blood and the like. The traditional Chinese medicine oral decoction achieves pharmacodynamic synergistic effects while having no toxic or side effects, and has obvious curative effects for uterine fibroids of patients who have hypomenorrhea, menorrhagia or underbelly pains during menstrual periods. The traditional Chinese medicine oral decoction is simple and practical, and can be prepared by patients themselves through a simple method.
The invention discloses a medicinal composition with an anti-fatigue effect as well as a preparation method and an application thereof. The medicinal composition comprises the following components in parts by weight: 8 to 50 parts of white paeony root, 4 to 30 parts of fructus aurantii, 2 to 15 parts of prepared polygonum multiflorum, 1 to 12 parts of lotus leaf, 3 to 25 parts of hairyvein agrimony and 2 to 20 parts of pseudo-ginseng. The method comprises the following steps of: preparing raw materials, preparing water-soluble active ingredients, preparing alcohol-soluble active ingredients and mixing and matching. A pharmaceutically acceptable carrier and/or an excipient are/is added into the medicinal composition to prepare pills, paste, sublimed preparation, tablets, capsules, oral liquid, powder and electuary. The medicinal composition is applied to preparing foods or medicines with the effects of relieving fatigue and/or treating mental fatigue and exercise induced fatigue. The medicinal composition is reasonable in formula, easy and convenient in preparation and accurate in curative effect. Due to the mouse toxicity and mental fatigue and exercise induced fatigue load swimming test, the medicinal composition does not have toxic or side effect and has obvious effects of relieving and eliminating the fatigues.
The purpose of this study is to test whether tadalafil causes subcutaneous adipose tissue to have a "beige" phenotype. Participants will be randomized to either placebo or tadalafil for 12 weeks. Investigators will study adipose metabolism using MRI scans and aspiration of subcutaneous adipose from the abdomen. In addition to MRI scans at room temperature, the investigators will use a cooling protocol to test the combined effects of tadalafil and on adipose metabolism. Investigators will also measure the effects of the drug on body composition. In addition to the study visits, participants will wear an activity tracker (Fitbit) and log their dietary intake several times using an online tool. There will be a small amount of radiation exposure. Participants will be compensated for participation in this study.
FIELD: medicine. SUBSTANCE: desired product is prepared by interaction of oxoline acid chloride with dimethylamino ethanol. The process is carried out at 80 C in dry benzene. Essential formula of desired product is CHNO HCl., its yield being 65 %. Melting point of desired product is 234-236 C. EFFECT: improves antibacterial activity of desired product. 4 tbl